Find clinical trials

Cardiac amyloidosis is an increasingly recognised cause of heart failure. This condition results in the heart becoming increasingly stiff and relying on an increased heart rate to maintain good heart function. Patients with pacemakers usually have their devices programmed to set their baseline heart rate at 60 beats per minute. There is growing evidence to suggest that patients with stiff hearts would have improved heart function and exercise capacity if the baseline heart rate was set closer to 75 beats per minute. This trial aims to determine if patients with cardiac amyloidosis who have a pacemaker have better heart function and quality of life if their pacemakers are set to a rate between 70 and 80 beats per minute compared to the standard 60 beats per minute.

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

The purpose of this trial is to find out whether a potential new treatment, the trial drug, Lu AF82422, is safe and effective in people living with Multiple Systems Atrophy (MSA). This trial will compare the effects of the trial drug, Lu AF82422, to placebo (inactive medication). Both the trial drug and placebo will be given as an infusion. Whether progression of MSA will be slowed is measured by a rating scale (questionnaire). The trial will also measure the amount of trial drug in participants blood and cerebrospinal fluid. Participants must have a reliable caregiver who will be available throughout the trial to complete caregiver observer questionnaires when carer/observer-reported outcomes are performed. The trial comprises 2 major periods: a 72-week double-blind PCP and an optional dose-blinded 72 week OLE period.

Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

The technological intervention underpinning the Medly Program is the digital therapeutic Medly20, a smartphone app with a built-in rules-based algorithm that provides heart failure (HF) patients with personalized self-care feedback based on daily entry of physiological parameters (e.g., weight, blood pressure, and heart rate) and symptoms from home, and continuous monitoring by their healthcare team through an integrated clinician dashboard. The clinical effectiveness and implementation of Medly have been studied through randomised controlled trials, feasibility trials, and observation studies over the past decade, but only in Ontario, Canada. The primary research aim is to determine the implementation factors and implementation outcomes of Medly for HF management at participating national and international hospitals in Alberta (Canada), Australia, and the United Kingdom.